| 0.938 | 0.002 | 0.938 | Vasodilator, coronary | | |
| 0.915 | 0.002 | 0.915 | Calcium channel blocker | | |
| 0.832 | 0.001 | 0.832 | Calcium antagonist | | |
| 0.829 | 0.003 | 0.829 | Calcium channel (voltage-sensitive) blocker | | |
| 0.822 | 0.001 | 0.822 | Calcium channel L-type blocker | | |
| 0.714 | 0.001 | 0.714 | Calcium channel activator | | |
| 0.707 | 0.004 | 0.707 | Vasodilator | | |
| 0.677 | 0.003 | 0.677 | Calcium channel L-type activator | | |
| 0.633 | 0.012 | 0.633 | Vasodilator, peripheral | | |
| 0.595 | 0.008 | 0.595 | Cardiotonic | | |
| 0.577 | 0.015 | 0.577 | Spasmolytic | | |
| 0.528 | 0.008 | 0.528 | Platelet aggregation inhibitor | | |
| 0.436 | 0.041 | 0.436 | Antithrombotic | | |
| 0.363 | 0.035 | 0.363 | Platelet antagonist | | |
| 0.394 | 0.077 | 0.394 | 15-Lipoxygenase inhibitor | | |
| 0.342 | 0.068 | 0.342 | Cholesterol antagonist | | |
| 0.279 | 0.011 | 0.279 | Alpha 2b adrenoreceptor antagonist | | |
| 0.275 | 0.013 | 0.275 | Platelet activating factor antagonist | | |
| 0.297 | 0.039 | 0.297 | Sigma receptor agonist | | |
| 0.264 | 0.007 | 0.264 | Neuropeptide Y1 antagonist | | |
| 0.253 | 0.01 | 0.253 | Alpha 2c adrenoreceptor antagonist | | |
| 0.242 | 0.018 | 0.242 | Antiadrenergic | | |
| 0.238 | 0.018 | 0.238 | Adrenaline antagonist | | |
| 0.254 | 0.041 | 0.254 | Non-steroidal antiinflammatory agent | | |
| 0.214 | 0.007 | 0.214 | Sphingomyelinase inhibitor | | |
| 0.299 | 0.095 | 0.299 | Transcription factor NF kappa B inhibitor | | |
| 0.216 | 0.013 | 0.216 | Alpha 1b adrenoreceptor antagonist | | |
| 0.209 | 0.009 | 0.209 | Alpha 1d adrenoreceptor antagonist | | |
| 0.256 | 0.059 | 0.256 | Interleukin antagonist | | |
| 0.217 | 0.038 | 0.217 | Diuretic | | |
| 0.182 | 0.008 | 0.182 | Toll-Like receptor 3 antagonist | | |
| 0.189 | 0.019 | 0.189 | Ca(v)2.2 blocker | | |
| 0.169 | 0.02 | 0.169 | TRPA1 agonist | | |
| 0.189 | 0.049 | 0.189 | Phospholipase A2 inhibitor | | |
| 0.154 | 0.021 | 0.154 | Alpha 2a adrenoreceptor antagonist | | |
| 0.138 | 0.007 | 0.138 | Beta adrenoreceptor antagonist | | |
| 0.207 | 0.076 | 0.207 | Psychostimulant | | |
| 0.164 | 0.034 | 0.164 | Alpha adrenoreceptor antagonist | | |
| 0.195 | 0.068 | 0.195 | P-glycoprotein inhibitor | | |
| 0.194 | 0.069 | 0.194 | Hepatoprotectant | | |
| 0.148 | 0.03 | 0.148 | Mediator release inhibitor | | |
| 0.124 | 0.005 | 0.124 | Mineralocorticoid receptor antagonist | | |
| 0.143 | 0.025 | 0.143 | Alpha 1a adrenoreceptor antagonist | | |
| 0.195 | 0.077 | 0.195 | Anesthetic general | | |
| 0.141 | 0.031 | 0.141 | Alpha 1 adrenoreceptor antagonist | | |
| 0.111 | 0.005 | 0.111 | Thromboxane synthase inhibitor | | |
| 0.119 | 0.018 | 0.119 | Adenosine A3 receptor antagonist | | |
| 0.202 | 0.11 | 0.202 | Hypoglycemic | | |
| 0.115 | 0.025 | 0.115 | Glutamate release inhibitor | | |
| 0.155 | 0.067 | 0.155 | GABA C receptor rho-2 antagonist | | |
| 0.167 | 0.084 | 0.167 | Lipocortins synthesis antagonist | | |
| 0.122 | 0.042 | 0.122 | Adenylate kinase inhibitor | | |
| 0.124 | 0.049 | 0.124 | GABA C receptor antagonist | | |
| 0.082 | 0.016 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | | |
| 0.105 | 0.044 | 0.105 | Alpha 2 adrenoreceptor antagonist | | |
| 0.134 | 0.075 | 0.134 | Farnesoid X receptor antagonist | | |
| 0.079 | 0.022 | 0.079 | Calcium channel T-type blocker | | |
| 0.074 | 0.023 | 0.074 | Beta 1 adrenoreceptor antagonist | | |
| 0.077 | 0.028 | 0.077 | Glutamate (mGluR6) antagonist | | |
| 0.225 | 0.178 | 0.225 | GABA C receptor rho-3 antagonist | | |
| 0.105 | 0.061 | 0.105 | Toll-Like receptor 4 antagonist | | |
| 0.08 | 0.036 | 0.08 | Phosphodiesterase III inhibitor | | |
| 0.114 | 0.071 | 0.114 | Calcium channel N-type blocker | | |
| 0.168 | 0.14 | 0.168 | Immunostimulant | | |
| 0.161 | 0.134 | 0.161 | Cyclic AMP phosphodiesterase inhibitor | | |
| 0.054 | 0.028 | 0.054 | Phosphorylase inhibitor | | |
| 0.171 | 0.145 | 0.171 | Peptidyltransferase inhibitor | | |
| 0.074 | 0.051 | 0.074 | Potassium channel (Tandem pore domain) blocker | | |
| 0.092 | 0.069 | 0.092 | Bile acid receptor antagonist | | |
| 0.06 | 0.039 | 0.06 | Dopamine uptake inhibitor | | |
| 0.036 | 0.017 | 0.036 | Transforming growth factor beta 2 antagonist | | |
| 0.09 | 0.078 | 0.09 | GABA C receptor rho-1 antagonist | | |
| 0.105 | 0.095 | 0.105 | Cyclooxygenase 3 inhibitor | | |
| 0.059 | 0.051 | 0.059 | Nitric oxide donor | | |
| 0.037 | 0.034 | 0.037 | Glutamate (mGluR1a) antagonist | | |
| 0.042 | 0.041 | 0.042 | Parathyroid hormone antagonist | | |